Huadao Biopharma has collected a $14.5m series B investment from NKY Medical Holdings to build out its cancer treatment technology.

China-based oncology technology developer Huadao Biopharma has completed a RMB100m ($14.5m) series B round led by chemical developer NKY Medical Holdings. The round also included a commitment from Ren Dalong, vice-president at pharmaceutical intermediate provider NKY Medical, according to a statement on Huadao’s WeChat account. Founded in 2017, Huadao is developing chimeric antigen receptor (CAR)…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.